Patent application number | Description | Published |
20090081287 | Pharmaceutical Composition Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 03-26-2009 |
20100168148 | Pharmaceutical formulation containing gelling agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 07-01-2010 |
20120108622 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-03-2012 |
20130217716 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 08-22-2013 |
20130245055 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 09-19-2013 |
20130261143 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 10-03-2013 |
20130261144 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 10-03-2013 |
20130261145 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 10-03-2013 |
20130303494 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 11-14-2013 |
Patent application number | Description | Published |
20100069390 | Method of treatment of attention deficit/hyperactivity disorder (ADHD) - The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 03-18-2010 |
20100173907 | Method of treatment of aggression - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 07-08-2010 |
20120115871 | METHOD OF TREATMENT OF DEPRESSION - The invention comprises a method of treatment of depression or depression-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 05-10-2012 |
20120302615 | METHOD OF TREATMENT OF CNS DISORDERS - The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity. | 11-29-2012 |
20130289035 | METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) - The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity. | 10-31-2013 |
20140187552 | METHOD OF TREATMENT OF AGGRESSION - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 07-03-2014 |
Patent application number | Description | Published |
20100142103 | Compact Secondary Substation Comprising A Fault Protection System, A Method For Fault Protection In A Compact Secondary Substation, And A Control Unit For Performing The Method - A Compact Secondary Substation including a fault protection system and a method for fault protection in Compact Secondary Substations (CSS). The CSS includes a Ring Main Unit (RMU), a transformer and a Low Voltage (LV) switchgear. The CSS includes a number of detectors, which detectors can be placed at least in one of the RMU, the transformer or in the LV switchgear, which detectors can be connected to a control unit, which control unit by fault detection by the detectors can activate a fast operating switch for grounding. By using the fast operating grounding switch and controlling this on the basis of the detectors placed inside the CSS, an active arc fault protection is achieved. The control unit also controls the fast operating grounding switch so that it works as a working grounding switch. | 06-10-2010 |
20120008255 | Encapsulation System For A Single Phase Encapsulated Channel Switchgear - The invention relates to an encapsulation system for a medium or low voltage switchgear. The switchgear includes several live phase conductors, and an encapsulation system, wherein the encapsulation system includes inner single phase encapsulations of respective phase. The encapsulation system further includes a fault handling system for handling of faults by means of adjusting the impedance of the inner single phase encapsulations. | 01-12-2012 |
20120119855 | THERMALLY INDEPENDENT OVERCURRENT TRIPPING DEVICE - Exemplary embodiments are directed to an electrical overcurrent tripping device for a circuit breaker. The tripping device includes an actuating member which in case of an overcurrent is driven to interact directly or indirectly with a movable contact piece of the circuit breaker to open a contact point in the circuit breaker if the overcurrent is exceeding a preset tripping threshold for a predetermined tripping delay time. The actuating member is coupled to a magnetic circuit such that the driving force acting on the actuating member is created by the magnetic field of the magnetic circuit, said magnetic field being induced by the overcurrent. The actuating member is coupled to an electromagnetic damping arrangement to set the tripping delay time, and is connected to a coupling spring configured to adjust the overcurrent tripping threshold. | 05-17-2012 |